In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Third Venture and Tasgen merge to form I-MAB

Executive Summary

Third Venture Biopharma and Tasgen Bio-Tech Co. Ltd. have merged to form a new firm called I-MAB Biopharma, which will focus on development in China of biologics for cancer and autoimmune diseases.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition

Related Companies

Advertisement
UsernamePublicRestriction

Register